Detalhe da pesquisa
1.
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects.
Immunity
; 54(8): 1636-1651, 2021 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348117
2.
Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission.
J Infect Dis
; 226(2): 225-235, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134185
3.
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Lancet
; 393(10174): 889-898, 2019 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30686586
4.
Chimpanzee Adenovirus Vector Ebola Vaccine.
N Engl J Med
; 376(10): 928-938, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25426834
5.
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
Lancet
; 391(10120): 552-562, 2018 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29217376
6.
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
PLoS Med
; 15(1): e1002493, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29364886
7.
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Lancet
; 385(9977): 1545-54, 2015 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25540891
8.
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.
J Infect Dis
; 211(4): 549-57, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25225676
9.
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
Lancet
; 384(9959): 2046-52, 2014 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25132507
10.
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.
J Infect Dis
; 208(3): 418-22, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23633407
11.
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.
Lancet HIV
; 6(10): e667-e679, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31473167
12.
Phase 1 study of pandemic H1 DNA vaccine in healthy adults.
PLoS One
; 10(4): e0123969, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25884189
13.
Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.
Travel Med Infect Dis
; 9(3): 126-34, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21208830